Alzheimer's Disease

Observational evidence for the connection is solidifying, and some clues are emerging about the mechanisms that may explain it.

Niacin, a form of vitamin B3 used to treat cardiovascular disease, helps immune cells in the brain fight neurodegenerative diseases such as Alzheimer’s in mice models, according to recent studies. Researchers hope that human clinical trials will swiftly follow.

A new study reveals a network of neurons that, when disrupted, impairs adaptation to new circumstances in several types of dementia.

A study that transfused plasma from active to inactive mice suggests the protein clusterin enhances cognition.

The Northwestern University researcher studies how adaptive immune cells influence neurodegenerative disease.

The long noncoding RNA MINCR, implicated in ALS and Alzheimer’s disease as well as several types of cancer, appears to function differently when present at high versus low levels.

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.

A new study links a variant of the apolipoprotein E gene called APOE ε4 to better memory in older age, even in the presence of amyloid plaques—a possible explanation for the variant’s persistence despite its association with an increased risk of Alzheimer’s disease.

Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.

Mice lacking irisin didn’t exhibit the cognition improvements that typically follow exercise, and in mouse models of Alzheimer’s disease, treatment with the hormone reduced cognitive decline.

Genetic, transcriptomic, and epigenetic data reveal molecular mechanisms tying these disorders to each other and to immune disfunction.

The US Food and Drug Administration has called for a federal investigation of its own regulatory review process after widespread criticism of its decision on Aduhelm.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.